Focus: Ipsen is a mid-cap biotechnology company headquartered in Tianjin, China, with 1,001-5,000 employees specializing in small molecules and biologics across oncology, endocrinology, neurology, and gastroenterology. Founded in 1986, the company maintains a diversified portfolio with significant revenue concentration in its flagship product.
Profile data last refreshed 7h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Ipsen to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ipsen
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ipsen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship asset generating 73% of company revenue but faces patent expiration in 4 years, representing existential business risk.
Second-largest revenue driver with established market penetration in endocrine disorders; generic lanreotide also in portfolio post-LOE.
Rare disease specialty product with long LOE protection (2041); Phase 3 trial ongoing for biliary atresia expansion.
Novel retinoid therapy for ultra-rare genetic disorder; Phase 2 expansion underway for hereditary exostoses represents pipeline momentum.
PPAR agonist in Phase 3 for autoimmune liver disease; recent regulatory filing expected to drive near-term catalyst.
Established neuro product with Phase 3 trial active in cervical dystonia; competitive landscape dominated by Botox (Allergan).
Niche oncology formulation with modest uptake; topoisomerase I inhibitor faces competition from newer regimens.
2 discontinued, 1 duplicate formulations not shown
8-K Filing: GERON CORP (GERN) (CIK 0000886744) — 8-K
8-K
Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias - Law360
Fired Ipsen Director Accuses The Pharmaceutical Co. Of Bias Law360
IPN.PA Stock Price, Quote & Chart | IPSEN (EPA:IPN) - ChartMill
IPN.PA Stock Price, Quote & Chart | IPSEN (EPA:IPN) ChartMill
8-K Filing: SUTRO BIOPHARMA, INC. (STRO) (CIK 0001382101) — EX-99.1
EX-99.1
Ipsen Pharma - Via Ritzau
Ipsen Pharma Via Ritzau
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR - GlobeNewswire
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR GlobeNewswire
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo